Table 4.
Multivariate regression analyses of factors associated with experiencing the adverse drug reaction blepharitis (including allergic response) with ripasudil treatment
| Covariate | Comparison | HR (95% CI) | p value |
|---|---|---|---|
| Sex | Female vs. male | 1.307 (1.013–1.687) | 0.040 |
| Age | ≥ 65 to < 75 vs. < 65 years | 0.759 (0.566–1.018) | 0.066 |
| ≥ 75 vs. < 65 years | 0.638 (0.470–0.866) | 0.004 | |
| Comorbid or a previous history of blepharitis | Yes vs. no | 2.178 (1.352–3.508) | 0.001 |
| History of pollen allergy | Yes vs. no | 1.645 (1.188–2.279) | 0.003 |
| History of medication allergy | Yes vs. no | 2.276 (1.477–3.507) | < 0.001 |
| Drug treatments for dry eye | Yes vs. no | 0.664 (0.467–0.944) | 0.022 |
| Number of concomitant pharmaceutical components for glaucoma used | 1 vs. 0 | 0.855 (0.554–1.318) | 0.478 |
| 2 vs. 0 | 0.985 (0.652–1.487) | 0.941 | |
| 3 vs. 0 | 0.637 (0.413–0.981) | 0.041 | |
| ≥ 4 vs. 0 | 0.346 (0.191–0.626) | < 0.001 |
CI confidence interval, HR hazard ratio